Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aichi Cancer Center Hospital, Aichi, Japan
Chronic hepatitis C treatment with bovine lactoferrin analyzed
November 7th, 2006
Recent research from Japan has reported on a randomized, double-blind, placebo-controlled trial of bovine lactoferrin (bLF) in patients with chronic hepatitis C virus (HCV). "Several studies have suggested that lactoferrin administration may decrease the serum level of HCV RNA in patients with chronic hepatitis C. The aim of the present study was to confirm the efficacy of orally administered bLF in patients with chronic hepatitis C," wrote H. Ueno and colleagues, Aichi Cancer Center Hospital. "The patients with chronic hepatitis C randomly received either oral bLF at a dose of 1.8 g daily for 12 weeks, or an oral placebo. The primary endpoint was...
Source: Drug Law Weekly (2006-11-07)
|
